Original Investigation  Critical Care Medicine January 30, 2024 Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial Babar A. Khan, Anthony J. Perkins, Sikandar Hayat Khan, et al JAMA Netw Open. 2024;7(1):e2353158. doi:10.1001/jamanetworkopen.2023.53158 Key Points Question  Does an intensive care unit (ICU) recovery program comprising a nurse care coordinator supporte...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OriginalPrediction of post-traumatic stress disorder in family members of ICU patients: a machine learning approachDupont T. et al. EditorialBalanced solution versus saline in critically ill patients: a new piece to the puzzle!Klouche K., Monnet X. and Zarbock A. Selective digestive decontamination: We must make an international decision on this 40-year old controversyCarlet J. Selective decontamination of the dige...

ICU Management & Practice, Volume 23 - Issue 4, 2023 Why Artificial Intelligence is Not Fixing the Problem of Sepsis in the Hospital The use of Artificial Intelligence in detecting sepsis, AI prediction/detection models and how these healthcare tools need to complement clinical expertise. The potential of Artificial Intelligence (AI) in healthcare has generated significant excitement and discussion. However, it's important to distinguish between the theo...

Original Investigation  January 31, 2024 Timing to First Whole Blood Transfusion and Survival Following Severe Hemorrhage in Trauma Patients Crisanto M. Torres, Kelly M. Kenzik, Noelle N. Saillant, et al JAMA Surg. Published online January 31, 2024. doi:10.1001/jamasurg.2023.7178 Key Points Question  Is the timing of first whole blood transfusion associated with improved early and late survival among adult trauma patients present...

ARTICLES|ONLINE FIRST A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial Raphaela I Lau, Qi Su, Ivan S F Lau, et al Lancet Infect Dis Published: December 07, 2023 DOI: https://doi.org/10.1016/S1473-3099(23)00685-0 Summary Background Post-acute COVID-19 syndrome (PACS) affects over 65 million individuals worldwide but treatment options are scarce. We aimed to as...

CRITICAL CARE: ORIGINAL RESEARCH| VOLUME 165, ISSUE 1, P110-127, JANUARY 2024 Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic Shock Michael Behnes, Jonas Rusnak, Sascha Egner-Walter, et al Chest 2024; 163: 110-127 Published: August 11, 2023 DOI:https://doi.org/10.1016/j.chest.2023.08.011 Background The spectrum of patients with cardiogenic shock (CS) has changed significantly over time. CS has become especially more common i...

ARTICLES|ONLINE FIRST Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study Yan Xie, Taeyoung Choi, Ziyad Al-Aly  Lancet Infect Dis Published: December 14, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00684-9 Summary Background Previous comparative analyses of people admitted to hospital for COVID-19 versus influenza evaluated the risk of death, hospital readmission, and a narrow set of health outcome...

ICU Management & Practice, Volume 23 - Issue 4, 2023 Individualisation of Mechanical Ventilation in Obstructive Lung Disease: Not All Patients Have ARDS Chronic obstructive pulmonary disease and asthma are pathologies par excellence with an obstructive pattern. It is important to understand the fundamentals of mechanical ventilation management in these patients. Therefore, it is crucial to perform proper measurement of respiratory mechanics in patients with...

ARTICLES|ONLINE FIRST Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial Evangelos J Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, et al Lancet Respir Med Published: January 03, 2024 DOI: https://doi.org/10.1016/S2213-2600(23)00412-5 Summary Background Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of ...

Perspective Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy Nicole Verdun, Peter Marks N Engl J Med January 24, 2024DOI: 10.1056/NEJMp2400209 Since the first such product was approved in 2017, chimeric antigen receptor (CAR) T-cell therapies have become important treatments for relapsed or refractory hematologic cancers, and the six products involving autologous CAR T cells that have been approved in the United States now cover a range of ind...